文献速递慢性肾脏病

Avenciguat对CKD患者白蛋白尿的影响:两项随机安慰剂对照试验

Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials.
PubMed 文献 · J Am Soc Nephrol · 2024-05-25

本文报告了两项设计相同的随机双盲安慰剂对照试验的预设汇总分析,评估可溶性鸟苷酸环化酶激活剂Avenciguat在糖尿病和非糖尿病CKD患者中的疗效与安全性。共500例患者随机接受安慰剂或Avenciguat 1、2、3 mg每日三次治疗20周。结果显示Avenciguat显著降低10小时尿和晨尿UACR,且耐受性良好,不良事件发生率与安慰剂相似。

要点

  • Avenciguat 1、2、3 mg每日三次均可降低CKD患者10小时尿和晨尿UACR。
  • Avenciguat总体耐受性良好,不良事件发生率低且与安慰剂相似。
  • 因不良事件停药率在Avenciguat组为4%–9%,安慰剂组为3%。

核心结论

  • Avenciguat可降低CKD患者白蛋白尿且耐受性良好。

研究设计与样本

  • 两项随机双盲安慰剂对照试验的预设汇总分析,设计相同。
  • 纳入500例成人CKD患者,eGFR≥20且<90 ml/min per 1.73 m2,UACR≥200且<3500 mg/g。
  • 患者随机接受安慰剂或Avenciguat 1、2、3 mg每日三次治疗20周,作为ACEI或ARB的辅助治疗。

主要发现

  • 第20周时,Avenciguat 1、2、3 mg组10小时尿UACR相对基线安慰剂校正几何均值变化分别为−15.5%(95%CI −26.4至−3.0)、−13.2%(95%CI −24.6至−0.1)、−21.5%(95%CI −31.7至−9.8)。
  • 第20周时,晨尿UACR相对基线安慰剂校正几何均值变化分别为−19.4%(95%CI −30.0至−7.3)、−15.5%(95%CI −26.9至−2.5)、−23.4%(95%CI −33.5至−11.8)。
  • Avenciguat 1、2、3 mg组因不良事件停药的患者数分别为5例(4%)、11例(9%)、11例(9%),安慰剂组为4例(3%)。

临床怎么用

  • 对于已接受ACEI或ARB治疗的CKD患者,加用Avenciguat可能进一步降低白蛋白尿。
  • Avenciguat总体耐受性良好,但需关注不良事件导致的停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Despite new treatments for CKD, kidney failure risk remains high, particularly where albuminuria remains. We report a prespecified pooled analysis of two randomized controlled trials assessing a soluble guanylate cyclase activator for CKD. Avenciguat led to improvements in albuminuria in patients with CKD with/without type 2 diabetes mellitus, with acceptable safety. BACKGROUND: Avenciguat is a novel, potent soluble guanylate cyclase activator in development for CKD. Two trials investigated avenciguat in diabetic (NCT04750577) and non-diabetic (NCT04736628) CKD. METHODS: A prespecified pooled analysis of two randomized, double-blind, placebo-controlled trials of identical design. Adults with CKD (eGFR ≥20 and <90 ml/min per 1.73 m2, urine albumin–creatinine ratio [UACR] ≥200 and <3500 mg/g) were randomized to 20 weeks of placebo or avenciguat 1, 2, or 3 mg three times daily (TID), adjunctive to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The primary end point was change from baseline in UACR in 10-hour urine at week 20, analyzed per protocol. The secondary end point was UACR change from baseline in first morning void urine at week 20. Safety was monitored throughout. RESULTS: Overall, 500 patients (mean age 62 years [SD 13]; mean eGFR 44 ml/min per 1.73 m2 [SD 18] and median 10-hour UACR 719 [interquartile range, 379–1285] mg/g) received placebo (n=122) or avenciguat 1 mg (n=125), 2 mg (n=126), or 3 mg (n=127) TID. All 243 patients in study one and 27 of 261 patients in study two had diabetes mellitus. Avenciguat 1, 2, and 3 mg TID reduced UACR in 10-hour and first morning void urine versus placebo throughout the treatment period. At week 20, placebo-corrected geometric mean changes (95% confidence interval) from baseline in UACR in 10-hour urine with avenciguat 1, 2, and 3 mg TID were −15.5% (−26.4 to −3.0), −13.2% (−24.6 to −0.1), and −21.5% (−31.7 to −9.8), respectively, analyzed per protocol. Corresponding changes in first morning void urine were −19.4% (−30.0 to −7.3), −15.5% (−26.9 to −2.5), and −23.4% (−33.5 to −11.8), respectively. Avenciguat was well tolerated; the overall frequency of adverse events was low and similar to placebo. The number of patients who discontinued the study drug because of adverse events with avenciguat 1, 2, and 3 mg TID were five (4%), 11 (9%), and 11 (9%), respectively, compared with four (3%) in the placebo group. CONCLUSIONS: Avenciguat lowered albuminuria and was well tolerated in patients with CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease, NCT04750577, and A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease, NCT04736628. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_06_27_ASN0000000000000418.mp3

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Cherney D, Gafor AHA, et al. Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials. J Am Soc Nephrol. 2024. PMID: 38795055. doi:10.1681/ASN.0000000000000418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。